GeneDx Holdings Corp (WGS)

Currency in USD
81.38
+2.48(+3.14%)
Closed·
81.380.00(0.00%)
·
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
79.0982.83
52 wk Range
55.17170.87
Key Statistics
Prev. Close
78.9
Open
79.62
Day's Range
79.09-82.83
52 wk Range
55.17-170.87
Volume
806.32K
Average Volume (3m)
616.11K
1-Year Change
-19.4257%
Book Value / Share
10.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WGS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
156.67
Upside
+92.51%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

GeneDx Holdings Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

GeneDx Holdings Corp Company Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

GeneDx Holdings Corp Earnings Call Summary for Q3/2025

  • GeneDx reported Q3 2025 EPS of -$0.27, missing forecast by 165.85%, while revenue beat expectations at $116.7 million, up 52% YoY
  • Stock fell 2.04% in pre-market trading despite revenue beat; company raised full-year guidance to $425-$428 million
  • Exome and genome revenues grew 66% YoY to $98.9 million; company holds 80% market share in U.S. clinical exome and genome testing
  • GeneDx targets 30% increase in testing volume, expanding into general pediatrician and NICU markets
  • Analysts maintain strong buy consensus; company expects continued growth despite operational challenges impacting profitability
Last Updated: 10/28/2025, 10:30 PM
Read Full Transcript

Compare WGS to Peers and Sector

Metrics to compare
WGS
Peers
Sector
Relationship
P/E Ratio
−113.4x28.7x−0.6x
PEG Ratio
−1.800.670.00
Price/Book
7.7x2.4x2.6x
Price / LTM Sales
5.6x1.6x3.3x
Upside (Analyst Target)
93.1%36.7%44.5%
Fair Value Upside
Unlock6.3%5.2%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 156.67
(+92.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy130.00+59.74%160.00MaintainFeb 24, 2026
BTIG
Buy170.00+108.90%200.00MaintainFeb 24, 2026
Jefferies
Buy150.00+84.32%180.00MaintainFeb 23, 2026
Canaccord Genuity
Buy170.00+108.90%-MaintainFeb 23, 2026
TD Cowen
Buy165.00+102.75%-MaintainFeb 23, 2026

Earnings

Latest Release
Feb 23, 2026
EPS / Forecast
-0.61 / 0.09
Revenue / Forecast
121.00M / 120.55M
EPS Revisions
Last 90 days

WGS Income Statement

People Also Watch

55.41
TEM
+3.17%
651.90
SNDK
+3.09%
124.67
ALAB
-2.72%
10.450
ONDS
+1.46%
69.07
OKLO
+4.15%

FAQ

What Is the GeneDx Holdings (WGS) Stock Price Today?

The GeneDx Holdings stock price today is 81.38 USD.

What Stock Exchange Does GeneDx Holdings Trade On?

GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for GeneDx Holdings?

The stock symbol for GeneDx Holdings is "WGS."

What Is the GeneDx Holdings Market Cap?

As of today, GeneDx Holdings market cap is 2.38B USD.

What Is GeneDx Holdings's Earnings Per Share (TTM)?

The GeneDx Holdings EPS (TTM) is -0.73.

When Is the Next GeneDx Holdings Earnings Date?

GeneDx Holdings will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is WGS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GeneDx Holdings Stock Split?

GeneDx Holdings has split 1 times.

How Many Employees Does GeneDx Holdings Have?

GeneDx Holdings has 1300 employees.

What is the current trading status of GeneDx Holdings (WGS)?

As of Feb 27, 2026, GeneDx Holdings (WGS) is trading at a price of 81.38 USD, with a previous close of 78.90 USD. The stock has fluctuated within a day range of 79.09 USD to 82.83 USD, while its 52-week range spans from 55.17 USD to 170.87 USD.

What Is GeneDx Holdings (WGS) Price Target According to Analysts?

The average 12-month price target for GeneDx Holdings is 156.67 USD, with a high estimate of 177 USD and a low estimate of 130 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +92.51% Upside potential.

What Is the WGS Premarket Price?

WGS's last pre-market stock price is 79.53 USD. The pre-market share volume is 210.00, and the stock has decreased by 0.63, or 0.80%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.